HIV-1 latently infected cells in vivo can be found in extremely low frequencies. Therefore, in vitro cell culture models have been used extensively for the study of HIV-1 latency. Often, these in vitro systems utilize defective viruses. Defective viruses allow for synchronized infections and circumvent the use of antiretrovirals. In addition, replication-defective viruses cause minimal cytopathicity because they fail to spread and usually do not encode env or accessory genes. On the other hand, replication-competent viruses encode all or most viral genes and better recapitulate the nuances of the viral replication cycle. The study of latency with replication-competent viruses requires the use of antiretroviral drugs in culture, and this mirrors the use of antiretroviral treatment (ART) in vivo. We describe a model that utilizes cultured central memory CD4+ T cells and replication-competent HIV-1. This method generates latently infected cells that can be reactivated using latency reversing agents in the presence of antiretroviral drugs. We also describe a method for the removal of productively infected cells prior to viral reactivation, which takes advantage of the downregulation of CD4 by HIV-1, and the use of a GFP-encoding virus for increased throughput.
Get full access to this article
View all access options for this article.
References
1.
FinziD, HermankovaM, PiersonT, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 1997; 278(5341):1295–1300.
2.
ChunTW, CarruthL, FinziD, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature, 1997; 387(6629):183–188.
3.
WongJK, HezarehM, GunthardHF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science, 1997; 278(5341):1291–1295.
4.
BrenchleyJM, HillBJ, AmbrozakDR, et al.: T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: Implications for HIV pathogenesis. J Virol, 2004; 78(3):1160–1168.
5.
ChomontN, El-FarM, AncutaP, et al.: HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med, 2009; 15(8):893–900.
6.
DeeksSG: HIV: Shock and kill. Nature, 2012; 487(7408):439–440.
7.
FolksTM, ClouseKA, JustementJ, et al.: Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Sci Acad USA, 1989; 86(7):2365–2368.
8.
PomerantzRJ, TronoD, FeinbergMB, and BaltimoreD: Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency. Cell, 1990; 61(7):1271–1276.
9.
AntoniBA, RabsonAB, KinterA, et al.: NF-kappa B-dependent and -independent pathways of HIV activation in a chronically infected T cell line. Virology, 1994; 202(2):684–694.
10.
JordanA, BisgroveD, and VerdinE: HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J, 2003; 22(8):1868–1877.
11.
Micheva-VitevaS, KobayashiY, EdelsteinLC, et al.: High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor. J Biol Chem, 2011; 286(24):21083–21091.
12.
DuvergerA, JonesJ, MayJ, et al.: Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol, 2009; 83(7):3078–3093.
13.
BosqueA and PlanellesV: Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood, 2009; 113(1):58–65.
14.
MariniA, HarperJM, and RomerioF: An in vitro system to model the establishment and reactivation of HIV-1 latency. J Immunol, 2008; 181(11):7713–7720.
15.
YangHC, XingS, ShanL, et al.: Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest, 2009; 119(11):3473–3486.
16.
TyagiM, PearsonRJ, and KarnJ: Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol, 2010; 84(13):6425–6437.
17.
ContrerasX, BarboricM, LenasiT, and PeterlinBM: HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Path, 2007; 3(10):1459–1469.
18.
SwiggardWJ, BaytopC, YuJJ, et al.: Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol, 2005; 79(22):14179–14188.
19.
SalehS, SolomonA, WightmanF, et al.: CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: A novel model of HIV-1 latency. Blood, 2007; 110(13):4161–4164.
20.
BosqueA and PlanellesV: Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells. Methods, 2011; 53(1):54–61.
21.
BonczkowskiP, De SpiegelaereW, BosqueA, et al.: Replication competent virus as an important source of bias in HIV latency models utilizing single round viral constructs. Retrovirology, 2014; 11:70.
22.
LahmHW and SteinS: Characterization of recombinant human interleukin-2 with micromethods. J Chromatogr, 1985; 326:357–361.
23.
AdachiA, GendelmanHE, KoenigS, et al.: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol, 1986; 59(2):284–291.
24.
HaradaS, KoyanagiY, and YamamotoN: Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science, 1985; 229(4713):563–566.
25.
HaertleT, CarreraCJ, WassonDB, et al.: Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives. J Biol Chem, 1988; 263(12):5870–5875.
26.
ClouseKA, PowellD, WashingtonI, et al.: Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol, 1989; 142(2):431–438.
27.
TriniteB, ChanCN, LeeCS, et al.: Suppression of Foxo1 activity and down-modulation of CD62L (L-selectin) in HIV-1 infected resting CD4 T cells. PloS One, 2014; 9(10):e110719.
28.
MessiM, GiacchettoI, NagataK, et al.: Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol, 2003; 4(1):78–86.
29.
ShanL, RabiSA, LairdGM, et al.: A novel PCR assay for quantification of HIV-1 RNA. J Virol, 2013; 87(11):6521–6525.
30.
DaleBM, AlvarezRA, and ChenBK: Mechanisms of enhanced HIV spread through T-cell virological synapses. Immunol Rev, 2013; 251(1):113–124.
31.
MiyoshiI, KubonishiI, YoshimotoS, and ShiraishiY: A T-cell line derived from normal human cord leukocytes by co-culturing with human leukemic T-cells. Gan, 1981; 72(6):978–981.
32.
LamaJ: The physiological relevance of CD4 receptor down-modulation during HIV infection. Curr HIV Res, 2003; 1(2):167–184.
33.
LevesqueK, FinziA, BinetteJ, and CohenEA: Role of CD4 receptor down-regulation during HIV-1 infection. Curr HIV Res, 2004; 2(1):51–59.
34.
LindwasserOW, ChaudhuriR, and BonifacinoJS: Mechanisms of CD4 downregulation by the Nef and Vpu proteins of primate immunodeficiency viruses. Curr Mol Med, 2007; 7(2):171–184.
35.
DavisZB, WardJP, and BarkerE: Preparation and use of HIV-1 infected primary CD4+ T-cells as target cells in natural killer cell cytotoxic assays. J Visual Exp: JoVE, 2011(49):2668.
36.
ArchinNM, LibertyAL, KashubaAD, et al.: Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature, 2012; 487(7408):482–485.
37.
NovisCL, ArchinNM, BuzonMJ, et al.: Reactivation of latent HIV-1 in central memory CD4(+) T cells through TLR-1/2 stimulation. Retrovirology, 2013; 10:119.
38.
SpinaCA, AndersonJ, ArchinNM, et al.: An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Path, 2013; 9(12):e1003834.
39.
MehlaR, Bivalkar-MehlaS, ZhangR, et al.: Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PloS One, 2010; 5(6):e11160.
40.
Pandelo JoseD, BartholomeeusenK, da CunhaRD, et al.: Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology, 2014; 462–463:328–339.
41.
NeilSJ, ZangT, and BieniaszPD: Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature, 2008; 451(7177):425–430.
42.
Van DammeN, GoffD, KatsuraC, et al.: The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe, 2008; 3(4):245–252.
43.
RamirezPW, FamigliettiM, SowrirajanB, et al.: Downmodulation of CCR7 by HIV-1 Vpu results in impaired migration and chemotactic signaling within CD4(+) T cells. Cell Rep, 2014; 7(6):2019–2030.
44.
RoyN, PaciniG, Berlioz-TorrentC, and JanvierK: Mechanisms underlying HIV-1 Vpu-mediated viral egress. Front Microbiol, 2014; 5:177.
45.
ShahAH, SowrirajanB, DavisZB, et al.: Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe, 2010; 8(5):397–409.
46.
ShanL, DengK, ShroffNS, et al.: Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity, 2012; 36(3):491–501.
47.
CollinsKL, ChenBK, KalamsSA, et al.: HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature, 1998; 391(6665):397–401.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
